Remepy Secures $36 Million in Series A Funding Led by O.G. Venture Partners and M Ventures

Remepy Raises $36 Million in Series A Funding

Remepy, a New York City-based company, has successfully raised $36 million in its Series A funding round. The company is at the forefront of redefining combination therapy by merging traditional pharmaceuticals with app-delivered protocols that have been clinically validated. This innovative approach aims to deliver a single, regulated prescription.

Investors and Leadership

The funding round was co-led by O.G. Venture Partners and M Ventures. Other participating investors include NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp.

Remepy was co-founded by Amir Amedi, who serves as the Chief Scientific Officer, along with Michal Tsur and Or Shoval, who are Co-CEOs. These leaders bring a wealth of experience and innovation to the company's strategic direction.

Use of Funds

While specific uses of the newly acquired funds were not detailed, companies in similar stages typically allocate such resources towards expanding their product offerings, scaling operations, and enhancing research and development capabilities.

Conclusion

This significant investment marks a pivotal step for Remepy as it continues to advance its unique approach to combination therapy. The backing from a diverse group of investors underscores the potential impact of their innovative solutions in the healthcare industry.